← ANALYST RATINGS · TIPRANKS

Evotec AG (EVO): analyst forecast and price target

$1.38 −2.82% close 16.10.26 · market cap $490M · Healthcare · Drug Manufacturers - Specialty & Generic
Price targets and ratings of

Analyst consensus

Moderate Buy

1 Buy0 Hold0 Sell

Ratings of 1 analysts in the last 3 months

12-month forecast

$4.00+189.9% upside

Based on 1 price targets given in the last 3 months, the average target is $4.00, the highest $4.00, the lowest $4.00. The average is +189.9% from the last price of $1.38.

$2.00$3.00$4.00Jan 26AprJulOctJan 27AprJulOctHigh$4.00Average$4.00Low$4.00
Highest target $4.00 Average target $4.00 Lowest target $4.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% H.C. Wainwright $4.00 Buy +189.9% Reiterated 14.10.26on TipRanks 06:30 +7.0%next day −0.6%
Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% Bank of America Securities $3.00 → $2.40−20.0% Sell +73.9% Reiterated 15.07.26on TipRanks 09:50 −6.5%next day −1.4% · 5 days −2.0%
Brendan Smith★★★★★★★★★★#458 · hits 56% · avg +27.3% TD Cowen $4.00 → $2.00−50.0% Hold +44.9% Downgrade 15.07.26on TipRanks Jul 14 19:30 −6.5%next day −1.4% · 5 days −2.0%

The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included

Best analysts covering Evotec AG

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Michael Ryskin★★★★★★★★★★Bank of America Securities · #1994
Hits 58%249 of 428 Average return +5.1%
1 year Michael Ryskin★★★★★★★★★★Bank of America Securities · #1994
Hits 58%249 of 428 Average return +5.1%
2 years Michael Ryskin★★★★★★★★★★Bank of America Securities · #1994
Hits 58%249 of 428 Average return +5.1%

Most profitable

3 months Michael Ryskin★★★★★★★★★★Bank of America Securities · #1994
Hits 58%249 of 428 Average return +5.1%
1 year Michael Ryskin★★★★★★★★★★Bank of America Securities · #1994
Hits 58%249 of 428 Average return +5.1%
2 years Michael Ryskin★★★★★★★★★★Bank of America Securities · #1994
Hits 58%249 of 428 Average return +5.1%

Recommendation trend

02572Oct 25111Nov111Dec111Jan 26Feb11Mar112Apr423May412Jun4112Jul311Aug311Sep3Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy444333
Buy211000
Hold001110
Sell322110

Earnings and sales forecast

Next report: 05.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-0.25 (from $-0.39 to $-0.14). Last quarter: $-0.15.

Sales

Next quarter’s sales estimate — $153M (from $147M to $162M). Last quarter: $167M.

Best top-analyst consensus in the sector · Healthcare

OVIDOvid Therapeutics
AXGNAxoGen
PTGXProtagonist TherapeuticsStrong Buy
ESTAEstablishment Labs HoldingsStrong Buy
REPLReplimune GroupStrong Buy
About Evotec AG
  • CEO: Christian Wojczewski
  • Employees: 4,553
  • Essener Bogen 7, Hamburg, HA, 22419, DE
  • www.evotec.com

Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.

Data from the stock’s TipRanks forecast page, read 408 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗